3 ms·
Merck had a sweetheart deal with Elsevier to publish a vanity journal which passed off marketing copy for Vioxx as "research". Why not point to the days of pho
by bitwize 14y ago
Merck had a sweetheart deal with Elsevier to publish a vanity journal which passed off marketing copy for Vioxx as "research".
Why not point to the days of phony, deadly cures being pushed on a naive population?
That's still going on, except these days the pushers of phony, deadly cures sound a lot like Alex3917. Hint: look for accusations of medical researchers being "shills of big pharma".
Vioxx gives us a handy, recent example of big pharma actually behaving badly,and they had to undermine science to do it. Just like the peddlers of unproven "alternative cures" -- and quite unlike, and to the dismay of, the medical research community.
- SilasX 14y agoIf it's being recommended for re-introduction even knowing what actually happened, and is responsible for the health of the overwhelming majority of those who took it, I don't think that counts as an example of a case where you "needed" to corrupt journals to get it approved.